Biosimilars for the management of inflammatory bowel diseases

economic considerations

Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L Lakatos

Research output: Contribution to journalArticle

Abstract

Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals, due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - Apr 6 2017

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Economics
Budgets
Health
Biological Therapy
Cost Savings
Therapeutics
Ulcerative Colitis
Crohn Disease
Health Status
Motivation
Costs
Sustainable development

Keywords

  • Journal Article

Cite this

Biosimilars for the management of inflammatory bowel diseases : economic considerations. / Gulacsi, Laszlo; Pentek, Marta; Rencz, Fanni; Brodszky, Valentin; Baji, Petra; Vegh, Zsuzsanna; Gecse, Krisztina B; Danese, Silvio; Peyrin-Biroulet, Laurent; Lakatos, Peter L.

In: Current Medicinal Chemistry, 06.04.2017.

Research output: Contribution to journalArticle

Gulacsi, L, Pentek, M, Rencz, F, Brodszky, V, Baji, P, Vegh, Z, Gecse, KB, Danese, S, Peyrin-Biroulet, L & Lakatos, PL 2017, 'Biosimilars for the management of inflammatory bowel diseases: economic considerations', Current Medicinal Chemistry. https://doi.org/10.2174/0929867324666170406112304
Gulacsi, Laszlo ; Pentek, Marta ; Rencz, Fanni ; Brodszky, Valentin ; Baji, Petra ; Vegh, Zsuzsanna ; Gecse, Krisztina B ; Danese, Silvio ; Peyrin-Biroulet, Laurent ; Lakatos, Peter L. / Biosimilars for the management of inflammatory bowel diseases : economic considerations. In: Current Medicinal Chemistry. 2017.
@article{6e25944d9ccf48e880ae2dc9f25f5275,
title = "Biosimilars for the management of inflammatory bowel diseases: economic considerations",
abstract = "Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals, due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75{\%} lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.",
keywords = "Journal Article",
author = "Laszlo Gulacsi and Marta Pentek and Fanni Rencz and Valentin Brodszky and Petra Baji and Zsuzsanna Vegh and Gecse, {Krisztina B} and Silvio Danese and Laurent Peyrin-Biroulet and Lakatos, {Peter L}",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2017",
month = "4",
day = "6",
doi = "10.2174/0929867324666170406112304",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Biosimilars for the management of inflammatory bowel diseases

T2 - economic considerations

AU - Gulacsi, Laszlo

AU - Pentek, Marta

AU - Rencz, Fanni

AU - Brodszky, Valentin

AU - Baji, Petra

AU - Vegh, Zsuzsanna

AU - Gecse, Krisztina B

AU - Danese, Silvio

AU - Peyrin-Biroulet, Laurent

AU - Lakatos, Peter L

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals, due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

AB - Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals, due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

KW - Journal Article

U2 - 10.2174/0929867324666170406112304

DO - 10.2174/0929867324666170406112304

M3 - Article

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -